Selexipag in pulmonary arterial hypertension: a comprehensive review.

被引：0
|
作者：
Dakwa, David S. [1 ]
Mella, Lisa [1 ]
Mella, Natalie [1 ]
Poulakos, Mara N. [1 ]
机构：
[1] Palm Beach Atlantic Univ, W Palm Beach, FL USA
来源：
PHARMACOTHERAPY | 2016年 / 36卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
500
引用
收藏
页码：E301 / E301
页数：1
相关论文
共 50 条
  • [41] Selexipag and the pulmonary hypertension continuum
    Maeder, Micha T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (01) : 215 - 218
  • [42] Selexipag for the Treatment of Schistosomiasis-associated Pulmonary Arterial Hypertension - The SELSCH Study
    Fernandes, C. J.
    Hoette, S.
    Alves, J.
    Salibe-Filho, W.
    Jardim, C.
    Souza, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [43] Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting
    Del Pozo, R.
    Blanco, I.
    Lopez-Meseguer, M.
    Escribano-Subias, P.
    Utrilla, A. Cruz
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 111 : 140 - 142
  • [44] Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study
    Galie, N.
    Channick, R.
    Chin, K.
    Frey, A.
    Gaine, S.
    Ghofrani, A.
    Hoeper, M.
    Lang, I.
    McLaughlin, V.
    Preiss, R.
    Rubin, L. J.
    Sitbon, O.
    Stefani, M.
    Tapson, V.
    Simonneau, G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S163 - S163
  • [45] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
    Fanous, Sherif M.
    Janmohamed, Munir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
  • [46] BUDGET-IMPACT OF SELEXIPAG FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Bilir, S. P.
    Beaudet, A.
    Zervoudaki, A.
    Lamprou, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A641 - A642
  • [47] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
    Asuka Furukawa
    Yuichi Tamura
    Hiroya Iwahori
    Masato Goto
    Narutaka Ohashi
    Teruo Okabe
    Akio Kawamura
    BMC Pulmonary Medicine, 17
  • [48] Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease
    van Dissel, Alexandra C.
    Post, Marco C.
    Sieswerda, Gertjan T.
    Vliegen, Hubert W.
    van Dijk, Arie P. J.
    Mulder, Barbara J. M.
    Bouma, Berto J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY CONGENITAL HEART DISEASE, 2021, 4
  • [49] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
    Yanaka, Kenichi
    Guillien, Alicia
    Soumagne, Thibaud
    Benet, Justin
    Piliero, Nicolas
    Picard, Francois
    Pison, Christophe
    Sitbon, Olivier
    Bouvaist, Helene
    Degano, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
  • [50] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Simonneau, Gerald
    Torbicki, Adam
    Hoeper, Marius M.
    Delcroix, Marion
    Karlocai, Kristof
    Galie, Nazzareno
    Degano, Bruno
    Bonderman, Diana
    Kurzyna, Marcin
    Efficace, Michela
    Giorgino, Ruben
    Lang, Irene M.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) : 874 - 880
12345